74 related articles for article (PubMed ID: 157801)
1. Phase I trial of N-(phosphonacetyl)-L-aspartate.
Erlichman C; Strong JM; Wiernik PH; McAvoy LM; Cohen MH; Levine AS; Hubbard SM; Chabner BA
Cancer Res; 1979 Oct; 39(10):3992-5. PubMed ID: 157801
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
[TBL] [Abstract][Full Text] [Related]
3. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
[TBL] [Abstract][Full Text] [Related]
7. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Karle JM; Anderson LW; Erlichman C; Cysyk RL
Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
[TBL] [Abstract][Full Text] [Related]
8. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
9. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
[TBL] [Abstract][Full Text] [Related]
10. Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer.
Hart RD; Ohnuma T; Holland JF
Cancer Treat Rep; 1980; 64(4-5):617-24. PubMed ID: 6448687
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
12. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
[TBL] [Abstract][Full Text] [Related]
13. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
14. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Doyle JA; Perry HO; Rubin J; Moertel CG
J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
16. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
[No Abstract] [Full Text] [Related]
17. Phase II study of PALA in advanced large bowel carcinoma.
Rubin J; Purvis J; Britell JC; Hahn RG; Moertel CG; Schutt AJ
Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
[No Abstract] [Full Text] [Related]
18. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Paridaens R; Mouridsen HT; Palshof T; Cocconi G; Van Oosterom A; Rotmensz N; Sylvester R; Heuson JC; Rozencweig M
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):67-70. PubMed ID: 6211361
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
Johnson RK; Inouye T; Goldin A; Stark GR
Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
[TBL] [Abstract][Full Text] [Related]
20. Response of psoriasis to N-phosphonacetyl-L-aspartate.
Earhart RH; DeConti RC; Rubin J; Ohnuma T
Lancet; 1981 Jun; 1(8232):1257-8. PubMed ID: 6112581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
